FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Minai-Azary Jennifer Lynn 2. Date of Event Requiring Statement (MM/DD/YYYY)
2/1/2021 

3. Issuer Name and Ticker or Trading Symbol Millendo Therapeutics, Inc. [MLND]
(Last)       (First)       (Middle)
C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Financial Officer /
(Street)
ANN ARBOR, MI 48104      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 8/21/2023  Common Stock  2969.0  $1.08  D   
Stock Option (right to buy)   (1) 5/27/2024  Common Stock  989.0  $2.69  D   
Stock Option (right to buy)   (1) 1/27/2026  Common Stock  12382.0  $4.44  D   
Stock Option (right to buy)   (1) 11/2/2026  Common Stock  12840.0  $8.47  D   
Stock Option (right to buy)   (2) 8/23/2028  Common Stock  11160.0  $16.4  D   
Stock Option (right to buy)   (3) 1/31/2029  Common Stock  18000.0  $10.48  D   
Stock Option (right to buy)   (4) 6/20/2029  Common Stock  7000.0  $11.59  D   
Stock Option (right to buy)   (5) 1/30/2030  Common Stock  20000.0  $7.94  D   
Stock Option (right to buy)   (6) 5/24/2030  Common Stock  20000.0  $2.0  D   

Explanation of Responses:
(1)  Shares subject to this option are fully vested.
(2)  Twenty-five percent (25%) of the shares subject to this option vested on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(3)  Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(4)  Twenty-five percent (25%) of the shares subject to this option vested on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(5)  Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(6)  Fifty percent (50%) of the shares subject to this option vested on December 31, 2020, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Minai-Azary Jennifer Lynn
C/O MILLENDO THERAPEUTICS, INC.
110 MILLER AVENUE, SUITE 100
ANN ARBOR, MI 48104


Chief Financial Officer

Signatures
/s/ Jennifer L. Minai-Azary 2/9/2021
**Signature of Reporting Person Date